A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
Bradley Vince(Altasciences Clinical Research Vince & Associates), Xiao-Jian Zhou(Idera Pharmaceuticals (United States)), Lynn R. Webster(Adherent Technologies (United States)), Joseph McCarville(Idera Pharmaceuticals (United States)), Daniel Gruener, Ricky Mofsen, Eric Lawitz(The University of Texas at San Antonio Health Science Center), Eileen Donovan(Idera Pharmaceuticals (United States)), William O’Riordan(Université Paris-Sud), Douglas L. Mayers(Idera Pharmaceuticals (United States)), John M. Hill(Dartmouth–Hitchcock Medical Center), J. Sullivan-Bolyai(Idera Pharmaceuticals (United States)), Jie Chen(Memorial Sloan Kettering Cancer Center), Abel Murillo
Cited by 23
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k